Zomedica (ZOMDF)
OTHER OTC:ZOMDF
Top Page
No summary available
Positive Factors
Revenue Growth
Consistent revenue growth over 14 consecutive quarters demonstrates strong market demand and effective sales strategies, supporting long-term business expansion.
Negative Factors
Profitability Challenges
Increasing net losses highlight ongoing profitability issues, which may hinder reinvestment and long-term financial health.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth over 14 consecutive quarters demonstrates strong market demand and effective sales strategies, supporting long-term business expansion.
Read all positive factors
Zomedica (ZOMDF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$110.73M
Dividend YieldN/A
Average Volume (3M)2.43M
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth10.20%
EPS Growth-35.75%
CountryUS
Employees144
SectorHealthcare
Sector Strength45
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding979,949,650
10 Day Avg. Volume1,820,838
30 Day Avg. Volume2,427,286
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.14
Enterprise Value/Revenue-0.60
Enterprise Value/Gross Profit-1.08
Enterprise Value/Ebitda0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$45.33M
Zomedica Business Overview & Revenue Model
Company Description
Zomedica Pharmaceuticals Corp. operates as a development stage veterinary diagnostic and pharmaceutical company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. The company was founded by Gerald ...
How the Company Makes Money
Zomedica Pharmaceuticals generates revenue primarily through the sale of its veterinary diagnostic and therapeutic products to veterinary clinics and hospitals. The company's key revenue streams include direct sales of its diagnostic platforms, su...
Zomedica Earnings Call Summary
Earnings Call Date:Mar 13, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Neutral
Zomedica's earnings call highlighted strong revenue growth, especially in the diagnostics segment, and successful international expansion. However, these positives were countered by significant challenges, including the delisting from the NYSE and an increased net loss. The company's strong liquidity position and product innovation are promising, but these are tempered by market and operational challenges.Positive Updates
Record Quarterly Revenue
Zomedica achieved a record quarterly revenue of $7.9 million for Q4 2024, reflecting an 8% growth over the prior year quarter.
Negative Updates
NYSE Delisting
Zomedica was delisted from the NYSE American Exchange due to failure to meet the minimum share price requirement, resulting in a transition to the OTCQB Market.
Read all updates
Q4-2024 Updates
Positive
Negative
Record Quarterly Revenue
Zomedica achieved a record quarterly revenue of $7.9 million for Q4 2024, reflecting an 8% growth over the prior year quarter.
Read all positive updates
Company Guidance
During the Zomedica Fourth Quarter 2024 financial results conference call, CEO Larry Heaton highlighted the company's achievements, including record revenues for the quarter at $7.9 million, marking 8% year-over-year growth. This contributed to a full-year revenue of $27.3 million, demonstrating strong performance in both the therapeutic devices and diagnostics segments. Heaton emphasized the success of their products, such as TRUFORMA and VetGuardian, which saw year-over-year growth of 65% and 95%, respectively. Additionally, the company maintained a healthy gross margin of 70.3%, exceeding the target range. Zomedica's liquidity stood strong with over $71 million, and the company reported a net loss of $7.2 million for the quarter. Heaton addressed concerns about the recent delisting from the NYSE American Exchange, explaining the transition to the OTCQB market and affirming the company's commitment to continue driving growth and achieving profitability.Zomedica Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.73M | 25.19M | 18.93M | 4.13M | 0.00 | 0.00 |
| Gross Profit | 14.77M | 17.32M | 13.65M | 3.05M | -530.02K | -787.61K |
| EBITDA | -54.27M | -29.39M | -15.34M | -19.57M | -16.38M | -19.00M |
| Net Income | -62.19M | -34.53M | -17.02M | -18.38M | -16.92M | -19.82M |
Balance Sheet | ||||||
| Total Assets | 214.12M | 253.20M | 279.61M | 280.40M | 66.14M | 4.18M |
| Cash, Cash Equivalents and Short-Term Investments | 76.88M | 90.50M | 115.09M | 194.95M | 61.99M | 510.59K |
| Total Debt | 2.08M | 2.73M | 1.74M | 1.38M | 1.87M | 0.00 |
| Total Liabilities | 11.27M | 13.18M | 12.22M | 9.51M | 15.08M | 2.09M |
| Stockholders Equity | 202.84M | 240.02M | 267.39M | 270.89M | 51.07M | 2.10M |
Cash Flow | ||||||
| Free Cash Flow | -19.64M | -20.62M | -12.70M | -14.80M | -16.26M | -16.32M |
| Operating Cash Flow | -23.83M | -15.97M | -11.67M | -14.28M | -16.24M | -15.63M |
| Investing Cash Flow | 12.01M | 1.58M | -155.88M | -71.93M | 1.01M | -686.93K |
| Financing Cash Flow | -223.65K | 0.00 | 8.00K | 219.16M | 76.71M | 14.89M |
Zomedica Technical Analysis
Negative
0.11
Price Trends
0.12
Negative
0.12
Negative
0.09
Positive
Market Momentum
>-0.01
Positive
39.01
Neutral
47.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZOMDF, the sentiment is Negative. The current price of 0.11 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.01 is Neutral, neither overbought nor oversold. The STOCH value of 47.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZOMDF.
Zomedica Risk Analysis
Zomedica disclosed 34 risk factors in its most recent earnings report. Zomedica reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zomedica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $110.73M | -1.28 | -28.16% | ― | 10.20% | -35.75% | |
59 Neutral | $764.65M | -3.32 | -170.83% | ― | ― | 37.37% | |
53 Neutral | $70.39M | -0.84 | -59.07% | ― | ― | -58.47% | |
48 Neutral | $152.81M | -12.49 | -100.49% | ― | -98.30% | 26.62% | |
45 Neutral | $57.86M | -1.67 | -82.79% | ― | 15.59% | 4.13% | |
44 Neutral | $81.62M | -0.98 | -99.62% | ― | -19.15% | 10.90% |
* Healthcare Sector Average
ZOMDF
Zomedica
0.11
0.06
114.00%
ATYR
aTyr Pharma
0.81
-2.18
-72.91%
VTVT
vTv Therapeutics
37.10
18.52
99.68%
RLMD
Relmada Therapeutics
7.38
7.07
2296.10%
PMVP
PMV Pharmaceuticals
1.35
0.31
29.81%
LUNG
Pulmonx
1.44
-3.48
-70.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―